NRC HEALTH NRC
Last close
21.53
2026-09-04
Market cap
$476.2M
2026-06-30 share count
52-week range
11.01 - 23.68
Valuation FY2025 figures against the last close
P/S3.5x
P/E0.4x
P/FCF30.2x
EV/EBITDA24.2x
Dividend yield2.3%
Diluted EPS50.00
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $137.4M | $143.1M | $148.6M | $151.6M | $148.0M | $133.3M | $128.0M | $119.7M | $117.6M | $109.4M |
| SG&A | $54.8M | $44.9M | $46.6M | $42.7M | $39.0M | $34.4M | $33.0M | $31.4M | $29.7M | $28.4M |
| Total operating expenses | $114.8M | $107.9M | $108.5M | $105.0M | $97.7M | $91.1M | $84.9M | $84.4M | $83.3M | $78.2M |
| Operating income | $22.6M | $35.2M | $40.0M | $46.5M | $50.3M | $42.7M | $43.0M | $35.3M | $34.2M | $31.2M |
| Interest expense | $4.8M | $2.6M | $862.0K | $1.2M | $1.7M | $1.8M | $2.1M | $1.5M | $82.0K | $190.0K |
| Pre-tax income | $17.8M | $32.7M | $40.0M | $42.8M | $48.6M | $41.5M | $40.5M | $34.7M | $34.3M | $31.4M |
| Income tax | $6.2M | $7.9M | $9.0M | $11.0M | $11.2M | $4.2M | $8.1M | $4.7M | $11.3M | $10.8M |
| Net income | $11.6M | $24.8M | $31.0M | $31.8M | $37.5M | $37.3M | $32.4M | $30.0M | $22.9M | $20.5M |
| EPS, basic | 50.00 | 1.05 | 1.26 | 1.28 | 1.47 | 1.48 | 1.30 | — | — | — |
| EPS, diluted | 50.00 | 1.04 | 1.25 | 1.27 | 1.46 | 1.45 | 1.26 | — | — | — |
| Shares, diluted (wtd. avg.) | $22.4M | $23.7M | $24.7M | $25.1M | $25.6M | $25.7M | $25.7M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.1M | $4.2M | $6.7M | $25.0M | $54.4M | $34.7M | $13.5M | $13.0M | $34.7M | $33.0M |
| Receivables | $11.1M | $11.1M | $12.4M | $14.5M | $13.7M | $13.9M | $11.6M | $11.9M | $14.8M | $10.9M |
| Total current assets | $20.2M | $19.6M | $24.4M | $43.7M | $73.7M | $54.1M | $29.2M | $28.4M | $52.3M | $47.1M |
| Property, plant and equipment | — | — | $28.2M | $17.2M | $12.4M | $11.7M | $13.5M | $14.2M | $12.4M | $11.8M |
| Goodwill | $66.2M | $66.2M | $61.6M | $61.6M | $61.6M | $57.3M | $57.9M | $57.8M | $58.0M | $57.9M |
| Other intangibles | $2.2M | $2.6M | $1.5M | $1.6M | $1.8M | $1.4M | $1.7M | $2.1M | $2.8M | $3.1M |
| Total assets | $134.9M | $132.5M | $122.4M | $130.5M | $157.5M | $133.4M | $110.7M | $108.0M | $127.3M | $120.6M |
| Accounts payable | $1.2M | $1.2M | $1.3M | $1.2M | $1.9M | $1.1M | $1.3M | $613.0K | $593.0K | $765.0K |
| Short-term debt | — | — | — | — | — | — | — | — | $1.1M | $2.7M |
| Total current liabilities | $36.6M | $35.9M | $36.2M | $33.4M | $40.4M | $31.7M | $38.2M | $47.1M | $32.3M | $31.5M |
| Long-term debt | $75.0M | $57.9M | $29.5M | $22.3M | $26.6M | $30.7M | $29.8M | $34.2M | $1.1M | $857.0K |
| Total liabilities | $120.9M | $101.3M | $73.5M | $58.4M | $72.2M | $69.1M | $77.8M | $88.9M | $37.3M | $37.8M |
| Retained earnings | -$17.3M | -$17.1M | -$30.5M | -$25.2M | -$36.1M | -$61.4M | -$93.4M | -$106.3M | $77.6M | $71.5M |
| Total equity | $14.0M | $31.3M | $49.0M | $72.0M | $85.3M | $64.3M | $32.9M | $19.1M | $90.0M | $82.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $26.4M | $34.6M | $38.1M | $36.3M | $46.3M | $40.6M | $40.9M | $39.8M | $28.1M | $26.8M |
| Stock-based compensation | $3.3M | $284.0K | $935.0K | $1.2M | $623.0K | $680.0K | $1.2M | $1.5M | $1.8M | $1.9M |
| Capital expenditure | $10.7M | $15.4M | $15.8M | $9.8M | $5.5M | $4.0M | $4.7M | $6.0M | $4.6M | $4.0M |
| Investing cash flow | -$10.7M | -$20.3M | -$15.8M | -$9.8M | -$8.5M | -$3.7M | -$4.7M | -$6.0M | -$6.1M | -$3.8M |
| Financing cash flow | -$15.8M | -$16.8M | -$40.7M | -$55.6M | -$18.2M | -$15.5M | -$36.3M | -$54.5M | -$21.1M | -$32.5M |
| Dividends paid | $11.0M | $11.5M | $36.4M | $21.0M | $9.2M | $10.5M | $31.3M | $16.9M | $16.9M | $28.6M |
| Buybacks | $20.2M | $30.9M | $19.1M | $27.6M | $4.1M | $10.0M | $4.7M | $8.0M | $4.1M | $601.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-015775.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $44.69B | 34.2x | 5.9% |
| INCY | INCYTE CORP | $25.32B | 19.8x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $16.50B | 38.7x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $13.77B | — | -0.9% |
| ABSI | Absci Corp | $1.51B | — | -38.2% |
| OABI | OmniAb, Inc. | $629.5M | — | -29.3% |
| MXCT | MAXCYTE, INC. | $132.1M | — | -5.7% |
| BIAF | bioAffinity Technologies, Inc. | $123.7M | — | -34.2% |